Foghorn Therapeutics Inc.
FHTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Foghorn Therapeutics Inc. (FHTX) is listed under Biotechnology. At a $118.8M market cap, Foghorn Therapeutics Inc. ranks as a micro-cap company within healthcare. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Market Cap
$118.8M
Beta
3.01
P/E (TTM)
—
P/E (Fwd)
-1.95
EPS (TTM)
$-0.98
EPS (Fwd)
$-1.03
ROE
—
ROA
-19.9%
Cash
$167.6M
Total Debt
$43.1M
Free CF
-$52.0M
52W Change
-51.5%
Annual Financials
Cash vs Debt
Where FHTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FHTX finished 59.44% below its 150-day moving average ($4.61) and 61.60% below its 200-day moving average ($4.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FHTX overbought or oversold?
At the October 20, 2026 close, FHTX's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $167.6M in cash comfortably exceeding the $43.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$52.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $19.2M (2022) to $30.9M (2025), reflecting a 61% increase over the period.
A beta of 3.01 means FHTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Foghorn Therapeutics Inc. and its sector.